Investor Relations

Company Overview

Algernon Pharmaceuticals is a Canadian clinical stage drug development and repurposing company investigating multiple drugs for unmet global medical needs. Algernon Pharmaceuticals is the parent company of a newly created private equity subsidiary called Algernon NeuroScience, that is advancing a program investigating a proprietary form of DMT for stroke and traumatic brain injury (TBI). The Company recently closed on its agreement with Seyltx Inc., a privately owned U.S. based drug development company, for the acquisition of Algernon’s NP-120 Ifenprodil research program to treat chronic cough and idiopathic pulmonary fibrosis, and also maintains a research program for chronic kidney disease.